益方生物2025年一季度盈利能力提升但现金流仍需关注

证券之星2025-04-30

近期益方生物(688382)发布2025年一季报，证券之星财报模型分析如下：盈利能力分析益方生物(688382)在2025年一季度实现了营业总收入818.9万元，同比下降4.85%。尽管收入有所下降，公司的盈利能力却有所提升，归母净利润为-5749.91万元，同比上升30.87%；扣非净利润为-5821.65万元，同比上升30.01%。毛利率达到85.89%，同比增加了62.05%，净利率为-...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2531742582?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-30 09:32","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2531742582","market":"sh","top_or_hot":-1,"title":"益方生物2025年一季度盈利能力提升但现金流仍需关注","media":"证券之星","content":"<div>\n<p>近期益方生物(688382)发布2025年一季报，证券之星财报模型分析如下：盈利能力分析益方生物(688382)在2025年一季度实现了营业总收入818.9万元，同比下降4.85%。尽管收入有所下降，公司的盈利能力却有所提升，归母净利润为-5749.91万元，同比上升30.87%；扣非净利润为-5821.65万元，同比上升30.01%。毛利率达到85.89%，同比增加了62.05%，净利率为-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430093546a46cf11a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>益方生物2025年一季度盈利能力提升但现金流仍需关注</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n益方生物2025年一季度盈利能力提升但现金流仍需关注\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-30 09:32 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430093546a46cf11a&s=b><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近期益方生物(688382)发布2025年一季报，证券之星财报模型分析如下：盈利能力分析益方生物(688382)在2025年一季度实现了营业总收入818.9万元，同比下降4.85%。尽管收入有所下降，公司的盈利能力却有所提升，归母净利润为-5749.91万元，同比上升30.87%；扣非净利润为-5821.65万元，同比上升30.01%。毛利率达到85.89%，同比增加了62.05%，净利率为-...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430093546a46cf11a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688382","symbol_name":"益方生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430093546a46cf11a&s=b","article_id":"2531742582","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430093546a46cf11a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2531742582","pubTimestamp":1745976720,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近期益方生物发布2025年一季报，证券之星财报模型分析如下：盈利能力分析益方生物在2025年一季度实现了营业总收入818.9万元，同比下降4.85%。每股净资产为3.06元，同比减少了8.76%，每股收益为-0.1元，同比增加了28.57%。尽管公司在盈利能力上有一定改善，但现金流和每股净资产的下降仍需引起重视。总结总体来看，益方生物在2025年一季度的盈利能力有所提升，毛利率和净利率均有显著增长。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159399":"现金流","688382":"益方生物","BK0239":"医药制造"},"translate_title":"Yifang Biotech's profitability will improve in the first quarter of 2025, but cash flow still needs attention","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159399":1,"688382":1},"content_text":"近期益方生物(688382)发布2025年一季报，证券之星财报模型分析如下：盈利能力分析益方生物(688382)在2025年一季度实现了营业总收入818.9万元，同比下降4.85%。尽管收入有所下降，公司的盈利能力却有所提升，归母净利润为-5749.91万元，同比上升30.87%；扣非净利润为-5821.65万元，同比上升30.01%。毛利率达到85.89%，同比增加了62.05%，净利率为-702.15%，同比增加了27.35%。偿债能力分析公司在偿债能力方面表现出色，货币资金为15.31亿元，虽然较去年同期的18.37亿元减少了16.67%，但仍保持在一个健康的水平。有息负债从748.03万元减少到415.79万元，减少了44.42%，表明公司债务压力有所减轻。现金流与运营状况每股经营性现金流为-0.11元，同比增加了31.07%，但仍然为负值。这提示投资者需要关注公司的现金流状况，尤其是近3年经营性现金流均值与流动负债的比例仅为-1309.93%，显示出公司在现金流管理方面存在一定的挑战。商业模式与未来发展益方生物的业绩主要依赖于研发驱动，这需要投资者仔细研究其研发成果和市场转化情况。每股净资产为3.06元，同比减少了8.76%，每股收益为-0.1元，同比增加了28.57%。尽管公司在盈利能力上有一定改善，但现金流和每股净资产的下降仍需引起重视。总结总体来看，益方生物在2025年一季度的盈利能力有所提升，毛利率和净利率均有显著增长。然而，现金流状况和每股净资产的下降提示公司在未来发展中需要进一步优化现金流管理和资本结构。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2531742582","isCrawlerRequest":true}